Table 3 |
||||
|
Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in Kawasaki disease (KD) with or without coronary artery lesions (CALs) |
||||
|
Characteristic |
KD with CALs (n = 9) |
KD without CALs (n = 31) |
P |
|
|
|
||||
|
Boys/girls, number |
4/5 |
18/13 |
0.000 |
|
|
Age, months |
27.1 (20.7) |
22.1 (15.6) |
0.001 |
|
|
Resistin, 102 ng/ml |
Acute stage |
0.46 (0.24) |
0.36 (0.26) |
0.268 |
|
Afebrile stage |
0.31 (0.20) |
0.22 (0.22) * |
0.266 |
|
|
Subacute stage |
0.15 (0.08)** ▲ |
0.13 (0.08) ** |
0.663 |
|
|
S100A12, 102 ng/ml |
Acute stage |
5.09 (2.78) |
5.40 (3.42) |
0.804 |
|
Afebrile stage |
4.22 (3.29) |
4.02 (3.63) |
0.883 |
|
|
Subacute stage |
2.52 (3.16) |
2.65 (2.53)** |
0.899 |
|
|
sRAGE, 102 pg/ml |
Acute stage |
2.97(1.99) |
3.01 (1.92) |
0.959 |
|
Afebrile stage |
5.93 (3.59)* |
5.70 (2.64)** |
0.833 |
|
|
Subacute stage |
7.06 (3.88)* |
6.77 (2.86)** |
0.802 |
|
|
|
||||
|
Results are mean (SD) unless stated otherwise. *P < 0.05, **P < 0.01 compared with acute stage; ▲P < 0.05 compared with group afebrile stage. |
||||
|
Qi et al. Arthritis Research & Therapy 2012 14:R251 doi:10.1186/ar4094 |
||||
